Bringing in an experienced leader and dealmaker would be wise for Gilead, says analyst

21 November 2018
gilead-big

With current Gilead Sciences (Nasdaq: GILD) chief executive John Milligan standing down at the end of the year, the announcement on his successor is one of the most eagerly-awaited in biopharma at present.

RBC Capital Markets analyst Brian Abrahams has made three major observations in a report about the appointment that was published on Tuesday.

Mr Abrahams suggests that a chief executive with a history of success in business development would be very well-received, given Gilead’s cash pile to spend on in-licensing deals and acquisitions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology